Immunex/Genentech Enbrel Manufacturing Deal Will Expand Capacity In 2004
Executive Summary
Genentech will be a second contract manufacturer for Immunex' Enbrel under an agreement between the two companies announced April 15
You may also be interested in...
Orencia Marketing Likely To Focus On Broader Mechanism Of Action
Bristol-Myers Squibb is setting the stage to differentiate Orencia from other biologic rheumatoid arthritis therapies with a broader mechanism of action claim
Orencia Marketing Likely To Focus On Broader Mechanism Of Action
Bristol-Myers Squibb is setting the stage to differentiate Orencia from other biologic rheumatoid arthritis therapies with a broader mechanism of action claim
Genentech Misses Enbrel Deadline; Amgen Contract Facility Not Ready
Genentech will not be reimbursed by Amgen for certain Enbrel manufacturing investments because Genentech's contract production line will not be ready on time, the company disclosed in its 2003 110-K filing